A detailed history of King Luther Capital Management Corp transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, King Luther Capital Management Corp holds 318,346 shares of CRL stock, worth $62.7 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
318,346
Previous 351,205 9.36%
Holding current value
$62.7 Million
Previous $95.2 Million 30.89%
% of portfolio
0.3%
Previous 0.43%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$206.39 - $268.73 $6.78 Million - $8.83 Million
-32,859 Reduced 9.36%
318,346 $65.8 Million
Q1 2024

May 13, 2024

SELL
$203.52 - $273.43 $3.18 Million - $4.27 Million
-15,629 Reduced 4.26%
351,205 $95.2 Million
Q4 2023

Feb 09, 2024

SELL
$164.52 - $238.84 $3.09 Million - $4.49 Million
-18,784 Reduced 4.87%
366,834 $86.7 Million
Q3 2023

Nov 13, 2023

SELL
$194.44 - $217.61 $3.17 Million - $3.54 Million
-16,289 Reduced 4.05%
385,618 $75.6 Million
Q2 2023

Aug 10, 2023

SELL
$183.71 - $210.25 $1.96 Million - $2.24 Million
-10,656 Reduced 2.58%
401,907 $84.5 Million
Q1 2023

May 11, 2023

SELL
$191.89 - $259.92 $3.46 Million - $4.69 Million
-18,033 Reduced 4.19%
412,563 $83.3 Million
Q4 2022

Feb 13, 2023

SELL
$197.11 - $250.07 $9.56 Million - $12.1 Million
-48,499 Reduced 10.12%
430,596 $93.8 Million
Q3 2022

Nov 10, 2022

SELL
$182.44 - $250.54 $6.94 Million - $9.54 Million
-38,065 Reduced 7.36%
479,095 $94.3 Million
Q2 2022

Aug 11, 2022

SELL
$204.13 - $302.4 $9.91 Million - $14.7 Million
-48,538 Reduced 8.58%
517,160 $111 Million
Q1 2022

May 11, 2022

BUY
$255.51 - $362.11 $2.71 Million - $3.84 Million
10,598 Added 1.91%
565,698 $161 Million
Q4 2021

Feb 14, 2022

BUY
$351.38 - $448.68 $3.22 Million - $4.11 Million
9,159 Added 1.68%
555,100 $209 Million
Q3 2021

Nov 10, 2021

SELL
$372.64 - $458.3 $794,468 - $977,095
-2,132 Reduced 0.39%
545,941 $225 Million
Q2 2021

Aug 13, 2021

BUY
$294.17 - $371.65 $5.45 Million - $6.88 Million
18,519 Added 3.5%
548,073 $203 Million
Q1 2021

May 12, 2021

BUY
$249.67 - $299.48 $13.2 Million - $15.8 Million
52,821 Added 11.08%
529,554 $153 Million
Q4 2020

Feb 10, 2021

BUY
$222.0 - $252.62 $12 Million - $13.7 Million
54,216 Added 12.83%
476,733 $119 Million
Q3 2020

Nov 12, 2020

BUY
$175.56 - $226.45 $2.45 Million - $3.16 Million
13,958 Added 3.42%
422,517 $95.7 Million
Q2 2020

Aug 12, 2020

BUY
$118.84 - $189.72 $1.25 Million - $1.99 Million
10,501 Added 2.64%
408,559 $71.2 Million
Q1 2020

May 13, 2020

SELL
$98.9 - $178.34 $359,600 - $648,444
-3,636 Reduced 0.91%
398,058 $50.2 Million
Q4 2019

Feb 12, 2020

BUY
$126.05 - $152.76 $4.47 Million - $5.42 Million
35,500 Added 9.69%
401,694 $61.4 Million
Q3 2019

Nov 12, 2019

BUY
$125.07 - $143.67 $2.8 Million - $3.22 Million
22,417 Added 6.52%
366,194 $48.5 Million
Q2 2019

Aug 12, 2019

BUY
$123.4 - $148.55 $27.2 Million - $32.8 Million
220,562 Added 179.01%
343,777 $48.8 Million
Q1 2019

May 10, 2019

BUY
$104.82 - $146.73 $3.23 Million - $4.52 Million
30,780 Added 33.3%
123,215 $17.9 Million
Q4 2018

Feb 12, 2019

BUY
$105.09 - $137.23 $2.22 Million - $2.91 Million
21,172 Added 29.71%
92,435 $10.5 Million
Q3 2018

Nov 13, 2018

SELL
$112.11 - $134.54 $141,819 - $170,193
-1,265 Reduced 1.74%
71,263 $9.59 Million
Q2 2018

Aug 13, 2018

SELL
$102.37 - $117.25 $812,817 - $930,965
-7,940 Reduced 9.87%
72,528 $8.14 Million
Q1 2018

May 08, 2018

SELL
$98.19 - $115.2 $527,280 - $618,624
-5,370 Reduced 6.26%
80,468 $8.59 Million
Q4 2017

Feb 12, 2018

SELL
$100.43 - $118.09 $499,639 - $587,497
-4,975 Reduced 5.48%
85,838 $9.4 Million
Q3 2017

Nov 13, 2017

BUY
$96.72 - $109.26 $8.78 Million - $9.92 Million
90,813
90,813 $9.81 Million

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $10B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track King Luther Capital Management Corp Portfolio

Follow King Luther Capital Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of King Luther Capital Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on King Luther Capital Management Corp with notifications on news.